David Sourdive

Co-Founder & EVP Strategic Initiatives • Cellectis

David Sourdive, Ph.D., is a co-founder of Cellectis and joined the Board of Directors in 2000.
Dr. Sourdive combines a strong scientific expertise with experience in managing industrial
programs bringing innovative technologies to industrial fruition. He served as Executive Vice
President, Corporate Development, from 2008 to 2016 and as Executive Vice President,
Technical Operations until July 2019. In addition to his role at Cellectis, Dr. Sourdive has also
served on the board of directors of the Mediterranean Institute for Life Sciences. David
Sourdive graduated from École Polytechnique, received his Ph.D. in molecular virology
at Institut Pasteur and completed a research fellowship in the Emory University Department
of Microbiology and Immunology. His management training is from the HEC (Challenge +) and
his decade-long experience in industrial program management was acquired at the
French Department of Defense (DGA) prior to Cellectis’ inception.

Also speaking

Amandine Breton

Director of MSAT & Analytical Sciences  • Orchard Therapeutics

Michelle Duquette

Director, Business Development – Cell Therapy • Invetech

Jens Hasskarl

Chief Medical Officer • Tigen Pharma

Event Info


Spotlight Roundtables

Take a look at the sample attendee list for Advanced Therapies Europe here.

Pub & Pints RSVP

Let us know you’re planning on attending.